Restatement of Net Asset Value(s)

Summary by AI ^BETAClose X

International Biotechnology Trust PLC has restated its unaudited cum income net asset value per share for several dates between December 29, 2025, and January 19, 2026, due to an administrative error concerning the non-accrual of an interim dividend. For example, the published NAV per share on December 29, 2025, was 1021.50, which has been revised to 1005.87. Similarly, the NAV on January 19, 2026, was revised from 1009.70 to 994.04. The company's service providers have implemented corrective measures and enhanced their procedures following this adjustment.

Disclaimer*

Intl. Biotechnology Trust PLC

10 February 2026

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

Restatement of Net Asset Value(s)

The Board of International Biotechnology Trust plc (the "Company") announces that, due to an administrative error relating to the non-accrual of the Company's most recent interim dividend, the Company's unaudited cum income net asset value ("NAV") per share has been restated for the following dates, as follows:

Date	Published Cum Income NAV per Share	Revised Cum Income NAV per Share
29/12/2025	1021.50	1005.87
30/12/2025	1016.30	1000.69
31/12/2025	1024.00	1008.35
02/01/2026	1013.20	997.59
05/01/2026	998.07	982.44
06/01/2026	1004.10	988.51
07/01/2026	1035.70	1020.10
08/01/2026	1025.30	1009.67
09/01/2026	1032.20	1016.53
12/01/2026	1010.90	995.29
13/01/2026	1007.40	991.72
14/01/2026	1031.00	1015.36
15/01/2026	1021.10	1005.51
16/01/2026	1013.60	997.96
19/01/2026	1009.70	994.04

As a result, the Company's service providers have implemented corrective measures and enhanced their procedures.

Enquiries:

Natalia de Sousa

Schroder Investment Management Limited

Tel: 020 7658 6000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END